NCT00450944View on ClinicalTrials.gov

Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 22, 2006

Primary Completion Date

October 27, 2008

Study Completion Date

April 1, 2010

Conditions
Leukemia
Interventions
BIOLOGICAL

deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins

Trial Locations (1)

10461

Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Albert Einstein College of Medicine

OTHER

NCT00450944 - Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter